Figures computed from official regulatory filings — .
Analysttarget 7.6 USD (-11%) · consensus 4/5 · 4 buy · 4 hold · 0 sell
Ownershipinsiders 7.25% · institutions 98.49% · short 9.8% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for MARAVAI LIFESCIENCES HOLDINGS, INC. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America. It operates through two segments: TRILINK and CYGNUS. The TRILINK segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, and oligonucleotide therapy, as well as molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, CleanCap capping technology-based oligonucleotide building blocks, and custom enzyme development and manufacturing; and research products for labeling and detecting proteins in cells and tissue samples. The CYGNUS segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, and antibody-based products to detect impurities during the production of biopharmaceutical products. It serves biopharmaceutical companies, and emerging biopharmaceutical and life sciences research companies; and academic research institutions and diagnostics companies. Maravai LifeSciences Holdings, Inc. was founded in 2014 and is headquartered in San Diego, California.
Market information source · Oct 5, 2026
SEC company identity · Oct 5, 2026
Open-market timeline · full history
15 buys4 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details | |
|---|---|---|---|---|---|
| Asarpota Rajesh | Other | $41.8K | SEC |
| Brust Bernd | Other | $214.1K | SEC |
| Asarpota Rajesh | Other | $42K | SEC |
| Brust Bernd | Other | $182.2K | SEC |
| Asarpota Rajesh | Other | $36K | SEC |
| Brust Bernd | Other | $173.2K | SEC |
| Asarpota Rajesh | Other | $419.1K | SEC |
| LUCIER GREGORY Ttrack record | Gift | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| LUCIER GREGORY Ttrack record | Gift | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| ORESHACK KURT | Sell | $127.5K | SEC |
| Brust Bernd | Other | $1.8M | Unusual size | SEC |
| ORESHACK KURT | Sell | $126.5K | SEC |
| DeFord John A | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| CUNNINGHAM SEAN LAURENCE | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| GRAY SUSANNAH | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| MIHAS CONSTANTINE S | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| LUCIER GREGORY Ttrack record | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| LUCIER GREGORY Ttrack record | Award | $202.8K | Unusual size | SEC |
| ECKERT R ANDREW | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Dolan Christine | Award | $9K | SEC |
| ORESHACK KURT | Award | $2.2K | SEC |
| ORESHACK KURT | Other | $123.1K | SEC |
| Dolan Christine | Other | $88.3K | SEC |
| Dolan Christine | Other | $106.8K | SEC |
| ORESHACK KURT | Other | $117.7K | SEC |